The ongoing challenge of acquired carbapenemases: a hospital outbreak of Klebsiella pneumoniae simultaneously producing VIM-1 and KPC-2.
A
A
Zioga
V
V
Miriagou
E
E
Tzelepi
E
E
Douzinas
M
M
Tsakiri
N J
NJ
Legakis
G L
GL
Daikos
L S
LS
Tzouvelekis
D000900:Anti-Bacterial Agents / Q000494:pharmacology; D001426:Bacterial Proteins / Q000378:metabolism*; D003428:Cross Infection / Q000453:epidemiology*; D004196:Disease Outbreaks; D006115:Greece / Q000453:epidemiology; D006801:Humans; D015378:Imipenem / Q000494:pharmacology; D007710:Klebsiella Infections / Q000453:epidemiology* / Q000382:microbiology; D007711:Klebsiella pneumoniae / Q000145:classification / Q000187:drug effects / Q000201:enzymology*; D000077731:Meropenem; D013845:Thienamycins / Q000494:pharmacology; D001618:beta-Lactamases / Q000378:metabolism*
D000900:Anti-Bacterial Agents; D001426:Bacterial Proteins; D013845:Thienamycins; D015378:Imipenem; D001618:beta-Lactamases; C547585:beta-lactamase KPC-2, Klebsiella pneumoniae; C525149:beta-lactamase VIM-12, Klebsiella pneumoniae; C063912:carbapenemase; D000077731:Meropenem